**May 24 (Saturday)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Time** | **Topics** | **Speakers** | **Moderators** |
| **13:15-13:20** | **Opening**  | **TASL President Chun-Jen Liu** 劉俊人 會長 台大 |
| **Topic 1: Oral Presentations I** |
| **13:20-13:32****13:32-13:40 (Q&A)** | Hepatitis B, vaccination and renal replacement therapy | **Chiuan-Bo Huang**黃詮博 醫師台大 | **Hung-Chih Yang**楊宏志 教授**台大** |
| **13:40-13:52****13:52-14:00** **(Q&A)**  | Prospective evaluation of HBV reactivation in patients receiving tyrosine kinase inhibitors | **Hung-Chih Chiu**邱宏智 醫師成大 | **Ting-Tsung Chang**張定宗 教授**成大** |
| **14:00-14:12****14:12-14:20 (Q&A)** | The study of the ferroptosis and mitochondrial dysfunction in metabolic dysfunction-associated steatotic liver disease (MASLD) | **Shu-Chi Wang**王述綺 副教授高醫 | **Chia-Yen Dai**戴嘉言 教授高醫 |
| **14:20-14:32****14:32-14:40 (Q&A)** | Clinical risk factors for advanced fibrosis in pathology-proven steatotic liver disease | **Chen-Te Huang**黃禎德 醫師台大 | **Huey-Ling Chen**陳慧玲 教授**台大** |
| **14:40-15:10** | **Coffee break**  |
| **Special Lecture (I)** |
| **15:10-15:40** | Clinical management and treatment strategy for MASLD, MetALD, and ALD | **Nobuharu Tamaki**Deputy director, Department of Gastroenterology and HepatologyMusashino Red Cross Hospital | **Han-Chieh Lin**林漢傑 教授北榮 |
| **Topic 2: Oral presentation II** |
| **15:40-15:52****15:52-16:00 (Q&A)** | Treatment of portal hypertension in patients with HCC | **Tsung-Chieh Yang**楊宗杰 醫師北榮 | **Ming-Chih Hou**侯明志 教授北榮 |
| **16:00-16:12****16:12-16:20****(Q&A)** | The novel role of LOC344887 in the enhancement of HCC progression via modulation of SHP1-regulated STAT3/HMGA2 signaling axis | **Yang-Hsiang Lin**林晹翔 博士林口長庚 | **Chau-Ting Yeh**葉昭廷 教授**林口長庚** |
| **16:20-16:32****16:32-16:40** **(Q&A)** | Optimizing resectability and outcomes in BCLC stage C HCC: advances and future perspectives | **Yuan-Hung Kuo**郭垣宏 醫師高雄長庚 | **Sheng-Nan Lu**盧勝男 教授**高雄長庚** |
| **17:00-18:00** | **Satellite symposium I Room 1001 (GSK)** |
| **16:50-17:30** | **Satellite symposium II Room 1003 (Novo Nordisk)** |
| **18:30-** | **Gala dinner**暨**TASL**師鐸獎頒獎典禮**Mentor award (For Registered TASL Members and invited Guests) -**台北喜來登B2福廳 |

**May 25 (Sunday)**

|  |  |
| --- | --- |
| **Time** | **Topics** |
| **8:30-9:10** | **Topic 4: SIG: immunology****Room 1005** | **Topic 5: SIG: MASLD****Room1006** | **Topic 6: Taiwan Clinical Trial Consortium (TCTC)****Room 1002** | **Topic 7: SIG: Basic research****Room 1007** |
| **Time** | **Topics** | **Speakers** | **Moderators** |
| **Room 1001 Special Lecture (II)** |
| **09:20-09:50** | Evolution of HBV treatment guidelines: towards a broader and more effective approach | **Sang-Hoon Ahn**Yonsei University College of Medicine | **Jia-Horng Kao**高嘉宏 教授台大 |
| **Special Lecture (III)** |
| **09:50-10:20** | The role of liquid biopsy in early diagnosis and immunotherapy response prediction in HCC | **Su Jong Yu****Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine** | **Pei-Jer Chen**陳培哲 院士台大 |
| **10:20-10:40** | **Coffee break**  |
| **Special Lecture (IV)** |
| **10:40-11:10** | Novel HBcAg, pHBcAg, and iTACT-HBcrAg assays: A New Era in HBV Monitoring and Precision Care | **Yasuhito Tanaka**Department of Gastroenterology and Hepatology,Kumamoto University | **Yun-Fan Liaw**廖運範 院士林口長庚 |
| **Keynote Lecture** |
| **11:10-11:50** | Basic and clinical aspects of Fontan-associated liver disease | **Tetsuo Takehara**Kansai Rosai Hospital | **Ming-Lung Yu**余明隆 教授高醫 |
| **12:00-13:00** | **Satellite symposium III Room 1001 (Gilead)** |
| **12:00-13:00** | **Satellite symposium IV Room 1002 (Roche)** |
| **Topic 8: The Changing Paradigm of Hepatology (I)** |
| **13:00-13:20** | Autophagy and mitochondrial dysfunctions in HBV-induced hepatocarcinogenesis | **Jaw-Ching Wu**吳肇卿 教授北榮 | **Chiaho Shih**施嘉和 教授高醫 |
| **13:20-13:40** | Novel therapy and strategy for chronic hepatitis B | **Wen-Juei Jeng**鄭文睿 教授林口長庚 | **Cheng-Yuan Peng**彭成元 教授中國醫藥 |
| **13:40-14:00** | Achieving the final milestone: Chronic hepatitis C virus elimination efforts in Taiwan | **Chen-Hua Liu**劉振驊 教授台大 | **Wan-Long Chuang**莊萬龍 教授高醫 |

**May 25 (Sunday)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Time** | **Topics** | **Speakers** | **Moderators** |
| **Topic 9: The Changing Paradigm of Hepatology (II)** |
| **14:00-14:20** | MASLD, alcohol-associated liver disease, and MetALD: Clinical features, diagnostic approaches, therapeutic strategies, and future perspectives | **Pin-Nan Cheng**鄭斌男 教授台南成大 | **Jee-Fu Huang**黃志富 教授高醫 |
| **14:20-14:40** | Genetic Interactions between DNAJA3 and TP53 in MASH-associated Hepatocellular Carcinoma | **Ching-Wen Chang**張瀞文 助理教授北醫 | **Chun-Yen Lin**林俊彥 教授**長庚大學** |
| **14:40-15:00** | The transformative role of artificial intelligence in liver research: Bridging basic science and clinical practice | **I-Cheng Lee**李懿宬 副教授**北榮** | **Shiu-Feng Huang**黃秀芬 教授**國衛院** |
| **15:00-15:10** | Closing remarks | **Chairman of TASL 2025 STC Chien-Wei Su**蘇建維 主席北榮 |

**The 2nd EALA meeting 2025**

**Topic: The Advances and Innovations of Hepatology**

**Date: May 24, 2025 (Sat) 13:10-17:10**

**Venue: Room 1002**

|  |  |  |  |
| --- | --- | --- | --- |
| **Time** | **Topics** | **Speakers** | **Moderators** |
| **13:10-13:30** | Registration |
| **13:30-13:40**  | Opening  | **Chun-Jen Liu****Yoon Jun Kim****Seoul National University Hospital****Tetsuo Takehara**  |
| **Session 1: Cirrhosis** |
| **13:40-14:00**  | Current management and future perspectives of covert hepatic encephalopathy in East Asia | **Takao Miwa****Gifu University Hospital, Gifu, Japan** | **Tatsuya Kanto** **Han-Chieh Lin**  |
| **14:00-14:20**  | Reversing Cirrhosis: Myth or Reality? Advances in Fibrosis Regression | **Soon Sun Kim** **Ajou University School of Medicine** |  |
| **14:20-14:40**  | Cracking the Code: Artificial intelligence-powered advances in liver cirrhosis and portal hypertension | **Hui-Chun Huang** **北榮** |  |
| **14:40-15:00**  | Break 1, group photos, connections |
| **Session 2: HCC** |
| **15:00-15:20** | Prophylactic corticosteroids to alleviate severe irAE of HCC – worthy of a second thought? | **Ann-Lii Cheng****台大** | **Jia-Horng Kao****Yoon Jun Kim** |
| **15:20-15:40** | Risk Stratification, Prognostication, and Complication Management in HCC: Insights from a Hepatologist | **Yeonjung Ha****CHA Bundang Medical Center, CHA University** |  |
| **15:40-16:00**  | Prediction of hepatocellular carcinoma | **Taro Yamashita****Department of Gastroenterology/Kanazawa University Graduate School of Medical Sciences** |  |
| **Session 3: Innovation in Hepatology** |
| **16:00-16:20** | GDF15 as a key driver and predictive biomarker in hepatocellular carcinoma: Evidence from basic and multicenter clinical studies | **Hayato Hikita****Graduate School of Medicine****The University of Osaka** | **Takumi Kawaguchi****Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine** **Woo Jin Chung** |
| **16:20-16:40** | Future Perspective of research for liver disease in the Asia-Pacific region | **Beom Kyung Kim****Department of Internal Medicine, Yonsei University College of Medicine** |  |
| **16:40-17:00** | Microbial and metabolic signatures associated with graft status in pediatric liver transplantation | **Kai-Chi Chang** **台大** |  |
| **17:00-17:10** | Closing Remarks | **Ming-Lung Yu** **Yoon Jun Kim** |  |

**報名資訊**

1. **線上報名：**

**報名網址:** [**http://tasl.org.tw/events/content.asp?eventsID=165**](http://tasl.org.tw/events/content.asp?eventsID=165)

為預先統計人數暨準備參與者相關資料，請於**5月10日**前於線上報

名。

5月24日報到當天領取餐券，晚宴憑券入場

晚宴地點：喜來登B2福廳(台北市中正區忠孝東路一段12號)。

1. **晚宴收費**(請事先報名)**：**TASL會員免費，TASL準會員：300元

非TASL會員繳費用$500元。恕不退費，恕不接受現場報名。

1. **晚宴繳費方式：TASL準會員及非TASL會員**請於5/10前ATM、手機、網路銀行轉帳/ 匯款至下列帳戶並註明匯款人姓名。

※ 請將轉帳截圖、匯款單影本掃描傳真或Email回傳秘書處，學會確認收到款項後即完成報名程序。

戶名：財團法人台灣肝臟研究暨教育基金會

銀行：合作金庫銀行006（臺大分行）

帳戶：1346765619456

1. **其它相關學分申請中。**

|  |  |  |
| --- | --- | --- |
| 1. **聯絡人**：楊紫柔
 | 電話: 02-2370-8856 | 傳真: 02-2370-8861 |
| **Email: tasl@tasl.org.tw** |